Previous 10 | Next 10 |
-- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Recei...
No CEO should be evaluated on their company's stock performance in a single year . Strategies often take several years to play out. When a company's fortunes depend on drug development, the timeline can be even longer. That's why no investor should take it too hard that Galapagos NV ...
Galapagos (GLPG) announced a share capital increase via subscription right exercises; issued 70,925 new ordinary shares for a total capital increase (including issuance premium) of €2.62M.In accordance with the rules of this program, CEO Onno van de Stolpe exercised 15K ...
Mechelen, Belgium; 4 December 2020, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 70,925 new ordinary shares on 4 December 2020, for a total capita...
Dosing is underway in a 60-subject Phase 2 clinical trial, MANGROVE, evaluating Galapagos NV's (GLPG) GLPG2737 in patients with autosomal dominant polycystic kidney disease.The primary efficacy endpoint is the mean percent change from baseline in height-adjusted total kidney volume at week 52...
Galapagos (GLPG) has dosed first participants in MANGROVE Phase 2 trial, evaluating GLPG2737 in patients with autosomal dominant polycystic kidney disease ((ADPKD)), a genetic disorder characterized by the growth of numerous cysts in the kidneys.The 60-subject trial's primary object...
Mechelen, Belgium; 1 December 2020, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces first dosing in the new MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in patients with autosomal dominant polycystic kidney disease (ADPKD). MANGROVE is a random...
Galapagos NV (GLPG) announces positive topline results from a Phase 2 proof-of-concept clinical trial, PINTA, evaluating GLPG1205 in 68 patients with ideopathic pulmonary fibrosis ((IPF)).The primary endpoint was the change from baseline over 26 weeks versus placebo in a measure of lung funct...
Placebo-adjusted improvement in forced vital capacity (FVC) decline of 42mL across treatment groups at 26 weeks Correlation between FVC decline and pulmonary lobar volume change observed, as measured by functional respiratory imaging (FRI) GLPG1205 planned to progress to...
Selvita to acquire Fidelta from Galapagos PR Newswire MECHELEN, Belgium and KRAKOW, Poland, Nov. 23, 2020 Strengthening Selvita's position as one of the largest preclinical contract research organizations in Europe Acquisition substantially expands Se...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...